Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Current Quarter	$-1.13	Next Quarter	$NA
Current Year	$-4.1	Next Year	$-2.75
QoQ Growth	NaN%	YoY Growth	+32.9%
3Y EPS CAGR	-11.8%	Target Price	$17.67
Consensus	Buy	Upside	+38.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENTA	$12.73	+4.95%	273.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENTA	$12.73	+4.9%	273.61K
3
4
5
6

ENTA

ENTA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Enanta Pharmaceuticals Inc. Data in Excel

Get Enanta Pharmaceuticals Inc. Data in Excel